Discontinued — last reported Q4 '23
Other
Unamortized Debt Issuance Expense
West Pharmaceutical Services Unamortized Debt Issuance Expense remained flat by 0.0% to $200.00K in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 50.0%, from $400.00K to $200.00K. Over 5 years (FY 2020 to FY 2025), Unamortized Debt Issuance Expense shows a downward trend with a -16.7% CAGR.
Analysis
StatementBalance Sheet Statement
SectionOther
CategoryLeverage
SignalContext dependent
VolatilityStable
First reportedQ4 2014
Last reportedQ4 2023
How to read this metric
An increase indicates recent debt issuance activity, while a decrease reflects the ongoing amortization of these costs.
Detailed definition
This represents the portion of costs incurred to issue debt that has not yet been recognized as interest expense on the...
Peer comparison
Standard across all firms with long-term debt; peers with higher debt turnover will show more frequent fluctuations.
Metric ID:
other_unamortized_debt_issuance_expenseHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $500.00K | $500.00K | $500.00K | $400.00K | $400.00K | $400.00K | $300.00K | $300.00K | $300.00K | $200.00K | $200.00K | $200.00K | $100.00K | $400.00K | $400.00K | $400.00K | $400.00K | $300.00K | $200.00K | $200.00K |
| QoQ Change | — | +0.0% | +0.0% | -20.0% | +0.0% | +0.0% | -25.0% | +0.0% | +0.0% | -33.3% | +0.0% | +0.0% | -50.0% | +300.0% | +0.0% | +0.0% | +0.0% | -25.0% | -33.3% | +0.0% |
| YoY Change | — | — | — | — | -20.0% | -20.0% | -40.0% | -25.0% | -25.0% | -50.0% | -33.3% | -33.3% | -66.7% | +100.0% | +100.0% | +100.0% | +300.0% | -25.0% | -50.0% | -50.0% |
Range$100.00K – $500.00K
CAGR-17.5%
Avg YoY Growth+10.1%
Median YoY Growth-25.0%
Unamortized Debt Issuance Expense at Other Companies
Frequently Asked Questions
- What is West Pharmaceutical Services's unamortized debt issuance expense?
- West Pharmaceutical Services (WST) reported unamortized debt issuance expense of $200.00K in Q1 2026.
- How has West Pharmaceutical Services's unamortized debt issuance expense changed year-over-year?
- West Pharmaceutical Services's unamortized debt issuance expense decreased by 50.0% year-over-year, from $400.00K to $200.00K.
- What is the long-term trend for West Pharmaceutical Services's unamortized debt issuance expense?
- Over 5 years (2020 to 2025), West Pharmaceutical Services's unamortized debt issuance expense has grown at a -16.7% compound annual growth rate (CAGR), from $500.00K to $200.00K.
- What does unamortized debt issuance expense mean?
- The portion of debt issuance costs that remains to be expensed over the remaining life of the debt.